bullish

Biopharma Week in Review - September 9, 2024

65 Views10 Sep 2024 22:23
Issuer-paid
Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20. TVTX celebrated full FDA approval of its IgAN drug, just in time for new KDIGO guidelines.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
chart-bar
  • Loading...
x